

EAPM DRAFT AGENDA



European Alliance for
Personalised Medicine

‘Lung Cancer & Early Diagnosis: The Evidence Exists for Lung Screening Guidelines in the EU’

Brussels, 10 December 2020
9.00 CET – 12.50 CET

Overview:

In the wake of several conferences on the subject in recent years and the launch of the European Beating Cancer Plan, the Brussels-based European Alliance for Personalised Medicine (EAPM) will be organising a roundtable on lung-cancer screening in association with **the European Respiratory Society, European Radiology Society** as well the **European Cancer Patient Coalition**

The idea is to present a case for the coordinated implementation of lung-cancer screening across the EU Region.

The title of the conference is *‘Lung Cancer & Early Diagnosis: The Evidence Exists for Lung Screening Guidelines in the EU’* and it will take place on **December 10th** in Brussels (albeit virtually).

One of the aims of the conference is to put forward an implementation action plan to facilitate the drawing-up of lung cancer screening guidelines by the EU.

Comprehensive screening programmes have been in place for some time in respect of several other cancers, but not so lung cancer, the biggest killer of all, while guidelines and best practices shared across Member States are urgently required.

Since EU Health Ministers unanimously adopted a set of recommendations on cancer screening in December 2003, systematic population-based screening for breast, cervical and colorectal cancers, for which evidence-based, feasible and efficient screening strategies exist, has been shown to bring about cost-effective interventions.

Fifteen years ago the Council Recommendation detailed the fundamental principles of the best practices in cancer screening, and urged Member States to take common actions to implement such programmes through a population-based approach with appropriate quality assurance at all levels.

A decade-and-half later, the majority of EU Member States now have population-based breast cancer screening programmes, for instance.

What next?

A stage-shift related to lung cancer screening will allow EU countries to reduce the cost of treatment given that treating early-stage lung cancer has half the cost of treatment at an advanced stage. The Alliance and its stakeholders realise that, among other elements, what is required in Europe is: continuous screening monitoring, with regular reports; assured consistency and enhanced quality of commented data for the screening reports; reference

EAPM DRAFT AGENDA

standards for quality and process indicators should be developed and adopted, On top of this, the integration of primary and secondary preventive strategies through comprehensive approaches is required.

All of the above will be discussed at the lung-cancer screening workshop, and it is envisaged that a coordinated plan will emerge, which will make its way to Commission policymakers and Member State health system chiefs.

Target Audience

Attendees will be drawn from key stakeholders from the community whose interaction will create a cross-sectoral, highly relevant and dynamic discussion forum. These participants will include healthcare professionals, decision makers, patient organisations, and European umbrella organizations representing interest groups and associations actively engaged in the field of Personalised Medicine. Each session will comprise panel discussions as well as Q&A sessions to allow best possible involvement of all participants

Expected outcomes

It is absolutely clear that it is necessary to formulate an EU Lung Screening strategy involving decision makers and regulators in the arena of public health, to enable the EU and Member States In order to provide a clear focus and to devote sufficient space to analysis, discussions during the conference will concentrate on how

- to assess and address obstacles to the integration of lung cancer screening guidelines into Europe's healthcare systems
- to identify best practices and their added value
- to outline the potential benefits of Lung Cancer Screening on public health and its impact on policy making

We sincerely hope you will be able to join us for this vital, high-level stakeholder virtual gathering on 10 December, and with that in mind please find the agenda below.

<https://register.gotowebinar.com/register/2948189108141848335>

Preliminary Agenda

Opening Plenary: Politics Meeting Science – The Need for Action
--

Session Chair: Denis Horgan, Genetic Alliance UK

- 09.00 Opening address
Cristian Busoi, *Member of the European Parliament*
Sirpa Pietikainen, *Member of the European Parliament*
- 09.20 A Call to Action for Lung Cancer Screening
Giulia Veronesi, *Ospedale San Raffaele, Milan, Italy (5 minutes)*
Luis Seijo Maceiras, *Co-director of the Department of Pulmonology at the Clínica Universidad de Navarra (5 minutes)*
Francesco De Lorenzo, *Past President, European Cancer Patient Coalition (5 minutes)*
- 10.15 The promise of screening guidelines for Lung Cancer Patients

EAPM DRAFT AGENDA

Richard Booton, *Clinical Senior Lecturer and Honorary Consultant Respiratory Physician at The University of Manchester and North West Lung Centre, Wythenshawe Hospital*

10.35 **Making Innovation a reality for patient**
Sebastian Schmidt, Siemens Healthineers
Xavier Franz, Varian Medical Systems

10.45 **Is it feasible?**
Ghebremedhin Ghebreigzabiher, *Health Attaché, Permanent Representation of Italy to the EU (TBC)*

10.55 – 11.45 **Session 2: Lung Cancer Screening - The Added Value for Society**

Session Chair: **Denis Horgan**, *Executive Director, EAPM*

Structured cooperation between health systems: The Role of Screening Guidelines.

Gabrijela Korže, *Health Attaché, Permanent Representation of Malta to the EU*

Croatia : Marko Jakopovic, *Head, Thoracic Oncology Unit, University Hospital Centre, Zagreb. Branka Čučević. Clinical for Lung Diseases Jordanovac. Fran Seiwerth, University Hospital Centre Zagreb (10 Minutes)*

Poland: Witold Rzyman, *Chief surgeon, Thoracic Surgery Department, Medical University of Gdansk (10 Minutes)*

Germany: Jens Vogel-Claussen, *Vice Chair of Institute of Diagnostic and Interventional Radiology, Hannover Medical School and Head of the Section for Cardiopulmonary Radiology of Institute of Diagnostic and Interventional Radiology, Hannover Medical School. (10 Minutes)*

Q&A

11.45-12.40 **Closing Session: Enabling quality through Lung Cancer Screening: Next Steps**

Session Chars: **Denis Horgan**, **EAPM Executive Director**

High Level Panel Discussion:

Boris Brkljačić, *President, European Society of Radiology*

Yolande Lievens, *Chair of department - Radiation Oncology (UZ Gent), Associate professor (Faculty of Medicine and Health Sciences, UGent)*

Joanna Chorostowska-Wynimko, *Secretary General, European Respiratory Society*

Anne-Marie Baird, *LuCE President*

12.40-12.50 **Closing**
Ewa Piasecka, *Health Attaché, Permanent Representation of Malta to the EU (TBC)*

Nicolas Gonzalez Casares, *Member of the European Parliament*

End of Meeting